EUROPE's biotechnology patent laws are to be challenged by the Netherlands in the European Court. The case will restart a longstanding debate over the legitimacy of patenting biotech inventions based on living organisms. This could prove to be a major setback for the European pharmaceutical industry. In May 1998, the European parliament passed a legislation permitting patents on organisms and gene sequences, with the exception of technology relating to the cloning of humans or the commercial use of embryos. But the Dutch government has challenged the law on procedural grounds. "We find patents for plants and animals unethical," said a spokesperson for the min- istry of economic affairs. The court case could take up to two years to resolve and may cause problems for drug companies seeking to file patents.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.